MAPK1 and chronic obstructive pulmonary disease: Notably, p38 inhibitors appear to offer superior therapeutic outcomes compared to steroids for specific subsets of COPD patients, given that steroids possess limited anti-inflammatory efficacy and are not recommended as standalone treatments for COPD [55, 174].